To cite this paper use one of the standards below:
Tuberculosis remains the leading cause of death among infectious diseases, causing an estimated 1.3 million deaths worldwide and surpassing COVID-19 and HIV. In 2023, approximately 10.6 million cases were reported, including diagnosed and undiagnosed infections, while 275.000 cases were drug-resistant, highlighting the urgent need for new therapies. Coumarins are natural products widely studied due to their diverse biological activities. Recent studies have shown that triazole and thiazole derivatives exhibit promising anti-tubercular activity, with minimum inhibitory concentrations (MICs) of 100 μM and 60 μM, respectively. In this work, a multicomponent synthesis was employed to access [3,2-c]thienocoumarins for evaluation against Mycobacterium tuberculosis. Using the Farapjour method, four analogs were obtained, with yields ranging from 8% to 31%. Biological screening approved TC-3 after screening, and MIC determination using the Resazurin Microtiter Assay is currently ongoing. Further analog synthesis and mechanistic studies are planned.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper